Gilead Sciences

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Switch study says patients prefer ViiV’s injectable HIV drug

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option

News

Gilead drops magrolimab for myelodysplastic syndromes

Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

News

Gilead, Teva cleared in $3.6bn ‘pay-for-delay’ trial

The jury in a California court has sided with Gilead Sciences and Teva in a lawsuit that accused the drugmakers of conspiring to delay the launch of generic versions of th

News